Your browser doesn't support javascript.
loading
Consumption of aspartame and other artificial sweeteners and risk of cancer in the Spanish multicase-control study (MCC-Spain).
Palomar-Cros, Anna; Straif, Kurt; Romaguera, Dora; Aragonés, Nuria; Castaño-Vinyals, Gemma; Martin, Vicente; Moreno, Victor; Gómez-Acebo, Inés; Guevara, Marcela; Aizpurua, Amaia; Molina-Barceló, Ana; Jiménez-Moleón, José-Juan; Tardón, Adonina; Contreras-Llanes, Manuel; Marcos-Gragera, Rafael; Huerta, José Mª; Pérez-Gómez, Beatriz; Espinosa, Ana; Hernández-Segura, Natalia; Obón-Santacana, Mireia; Alonso-Molero, Jessica; Burgui, Rosana; Amiano, Pilar; Pinto-Carbó, Marina; Olmedo-Requena, Rocio; Fernández-Tardón, Guillermo; Santos-Sánchez, Vanessa; Fernández de Larrea-Baz, Nerea; Fernández-Villa, Tania; Casabonne, Delphine; Dierssen-Sotos, Trinidad; Ardanaz, Eva; Dorronsoro, Ane; Pollán, Marina; Kogevinas, Manolis; Lassale, Camille.
Affiliation
  • Palomar-Cros A; Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
  • Straif K; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
  • Romaguera D; CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain.
  • Aragonés N; Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
  • Castaño-Vinyals G; Boston College, Boston, Massachusetts, USA.
  • Martin V; Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
  • Moreno V; Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain.
  • Gómez-Acebo I; CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Madrid, Spain.
  • Guevara M; CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain.
  • Aizpurua A; Public Health Division, Department of Health, Madrid, Spain.
  • Molina-Barceló A; Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
  • Jiménez-Moleón JJ; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
  • Tardón A; CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain.
  • Contreras-Llanes M; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Marcos-Gragera R; CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain.
  • Huerta JM; The Research Group in Gene-Environment and Health Interactions (GIIGAS)/Institute of Biomedicine (IBIOMED), Universidad de León, León, Spain.
  • Pérez-Gómez B; CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain.
  • Espinosa A; Cancer Epidemiology Research Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.
  • Hernández-Segura N; Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
  • Obón-Santacana M; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain.
  • Alonso-Molero J; CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain.
  • Burgui R; Faculty of Medicine, University of Cantabria, Santander, Spain.
  • Amiano P; IDIVAL-Instituto de investigación sanitaria Valdecilla, Santander, Spain.
  • Pinto-Carbó M; CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain.
  • Olmedo-Requena R; Institute of Public and Occupational Health of Navarre (ISPLN), Pamplona, Spain.
  • Fernández-Tardón G; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
  • Santos-Sánchez V; Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastian, Spain.
  • Fernández de Larrea-Baz N; Biodonostia Health Research Institute, Epidemiology of Chronic and Communicable Diseases Group, San Sebastián, Spain.
  • Fernández-Villa T; Cancer and Public Health Research Unit, Foundation for the Promotion of Health and Biomedical Research, (FISABIO-Public Health), Valencia, Spain.
  • Casabonne D; CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain.
  • Dierssen-Sotos T; Instituto de Investigación Biosanitaria ibs.GRANADA, Complejo Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain.
  • Ardanaz E; Departamento de Medicina Preventiva y Salud Pública, Universidad de Granada, Granada, Spain.
  • Dorronsoro A; CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain.
  • Pollán M; University of Oviedo, Health Research Institute of Asturias (ISPA), Asturias, Spain.
  • Kogevinas M; Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain.
  • Lassale C; Grupo de investigación en Epidemiología Clínica, Ambiental y Transformación Social (EPICAS), Departamento de Sociología, Trabajo Social y Salud Pública, Universidad de Huelva, Huelva, Spain.
Int J Cancer ; 153(5): 979-993, 2023 Sep 01.
Article in En | MEDLINE | ID: mdl-37323037
ABSTRACT
Use of artificial sweeteners (AS) such as aspartame, cyclamate, saccharin and sucralose is widespread. We evaluated the association of use of aspartame and other AS with cancer. In total 1881 colorectal, 1510 breast, 972 prostate and 351 stomach cancer and 109 chronic lymphocytic leukaemia (CLL) cases and 3629 population controls from the Spanish Multicase-Control (MCC-Spain) study were recruited (2008-2013). The consumption of AS, from table-top sweeteners and artificially sweetened beverages, was assessed through a self-administered and validated food frequency questionnaire (FFQ). Sex-specific quartiles among controls were determined to compare moderate consumers (aspartame-containing products and other AS. Unconditional logistic regression models were used to estimate adjusted OR and 95%CI, and results were stratified by diabetes status. Overall, we found no associations between the consumption of aspartame or other AS and cancer. Among participants with diabetes, high consumption of other AS was associated with colorectal cancer (OR = 1.58, 95% CI 1.05-2.41, P trend = .03) and stomach cancer (OR = 2.27 [0.99-5.44], P trend = .06). High consumption of aspartame, was associated with stomach cancer (OR = 2.04 [0.7-5.4], P trend = .05), while a lower risk was observed for breast cancer (OR = 0.28 [0.08-0.83], P trend = .03). In some cancers, the number of cases in participants with diabetes were small and results should be interpreted cautiously. We did not find associations between use of AS and cancer, but found associations between high consumption of aspartame and other AS and different cancer types among participants with diabetes.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach Neoplasms / Diabetes Mellitus Type of study: Etiology_studies / Risk_factors_studies Limits: Female / Humans / Male Country/Region as subject: Europa Language: En Journal: Int J Cancer Year: 2023 Type: Article Affiliation country: Spain

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach Neoplasms / Diabetes Mellitus Type of study: Etiology_studies / Risk_factors_studies Limits: Female / Humans / Male Country/Region as subject: Europa Language: En Journal: Int J Cancer Year: 2023 Type: Article Affiliation country: Spain